Skip to main content
SpringerLink
Log in

Dynamics of tumour angiogenesis: Effect of razoxane-induced growth rate slowdown

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2002; 2: 727–39.

    Article  CAS  Google Scholar 

  2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–6.

    Article  PubMed  CAS  Google Scholar 

  3. Salsbury AJ, Burrage K, Hellmann K. Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic. BMJ 1970; 4: 344–6.

    PubMed  CAS  Google Scholar 

  4. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987–9.

    Article  PubMed  CAS  Google Scholar 

  5. Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: A new type of drug action. BMJ 1972; 1: 597–601.

    Article  PubMed  CAS  Google Scholar 

  6. Hellmann K, Burrage K. Control of malignant metastases by ICRF 159. Nature 1969; 224: 273–5.

    Article  PubMed  CAS  Google Scholar 

  7. Willis R. The Spread of Tumours in the Human Body. London: Butterworth 1952; 115.

  8. Hellmann K. Serendipity in cancer chemotherapy. New Sci J 1971; 21: 111–3.

    Google Scholar 

  9. Salsbury AJ, Burrage K, Hellmann K. Histological analysis of the antimetastatic effect of 1,2-bis(3,5-dioxopiperazine-l-yl)propane. Cancer Res 1974; 34: 843–9.

    PubMed  CAS  Google Scholar 

  10. Heston WDW, Kadmon D, Fair WR. Effect of high dose diethylstilbestrol and ICRF 159 on the growth and metastases of the R3327 MAT-LyLu prostate-derived tumor. Cancer Lett 1981; 13: 139–45.

    Article  PubMed  CAS  Google Scholar 

  11. Pollard M, Burleson GR, Luckert PH. Interference with in vivo growth and metastasis of prostate adenocarcinoma (PA-III) by ICRF 159. Prostate 1981; 2: 1–9.

    PubMed  CAS  Google Scholar 

  12. Barker Grimshaw M, Davies RW, Hall WS. Combination therapy of a mouse sarcoma using razoxane and electron irradiation. Br J Cancer 1981; 44: 117–23.

    Google Scholar 

  13. Young SW, Hollenberg NK, Meinking TL et al. The influence of ICRF 159 on lymphatic and hematogenous metastases from rabbit V2 carcinoma. Unpublished report for USPHS Grants GM18674, GMO1910 and HL20895.

  14. Gosalvez M, Blanco M, Hunter J et al. Effects of Anticancer agents on the respiration of isolated mitochondria and tumor cells. Eur J Cancer 1974; 10: 567–74.

    PubMed  CAS  Google Scholar 

  15. Hallowes RC, West DG, Hellmann K. Cumulative cytostatic effect of ICRF 159. Nature 1974; 247: 487–90.

    Article  PubMed  CAS  Google Scholar 

  16. Sandberg J, Goldin A. Use of first generation transplants of a slow growing solid tumor for the evaluation of new cancer chemotherapeutic agents. Cancer Chemother Rep 1971; 55 1: 233–8.

    PubMed  CAS  Google Scholar 

  17. Hellmann K, Tucker DF. Tumor growth in grids on chorio-allantoic membranes of chick embryos. Cancer Chemother Rep 1965; 47: 73–9.

    PubMed  CAS  Google Scholar 

  18. Gitterman CO, Luell S. Chemotherapeutic studies on metastasis of human epidermoid carcinoma (H.Ep)#3 in the embryonated chick egg. In Garattini S, Franchi G (eds): Chemotherapy of Cancer Dissemination and Metastasis. New York: Raven Press 1973; 279–91.

    Google Scholar 

  19. Sharpe HBA, Field EO, Hellmann K. Mode of action of the cytostatic agent ICRF 159. Nature 1970; 226: 524–6.

    Article  PubMed  CAS  Google Scholar 

  20. Hellmann K, Williamson CJ, Sargent JM. Effect of Dexrazoxane on the cell cycle and intracellular ATP levels in K562 cells. Br Pharmacol Soc, Winter 2003 meeting; Abstract (in press).

  21. O'Connell MJ, Begg CB, Silverstein MN et al. Randomized clinical trial comparing two dose regimens of ICRF 159 in refractory malignant lymphoma. Cancer Treat Rep 1980; 64: 1355–8.

    PubMed  Google Scholar 

  22. Flannery EP, Corder MP, Sheehan WW et al. Phase II study of ICRF 159 in non-Hodgkin's lymphomas. Cancer Treat Rep 1978; 62: 465–7.

    PubMed  CAS  Google Scholar 

  23. Gilbert JM, Hellmann K, Evans M et al. Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: Five year follow-up. Br J Surg 1986; 73: 446–50.

    PubMed  CAS  Google Scholar 

  24. Hellmann K, Gilbert J, Evans M et al. Effect of razoxane on metastases from colorectal cancer. Clin Exp Metastasis 1987; 5: 3–8.

    Article  PubMed  CAS  Google Scholar 

  25. Taylor RH, Gilbert JM, Evans M et al. Prospective serial liver ultrasound scanning in resectable colorectal cancer treated with adjuvant razoxane. Clin Exp Metastasis 1984; 2: 321–31.

    Article  PubMed  CAS  Google Scholar 

  26. Atherton DJ, Wells RS, Hellmann K. Razoxane (ICRF 159) in psoriasis. Lancet 1976; ii: 1296.

    Article  Google Scholar 

  27. Horton JJ, Wells RS. Razoxane: A review of 6 years' therapy in psoriasis. Br J Dermatol 1983; 109: 669–73.

    PubMed  CAS  Google Scholar 

  28. Mom A, Aresca S, Fuente G et al. Razoxane in the treatment of Psoriatic Patients resistant to or intolerant of PUVA, methotrexate and etretinate. Acta Dermatovener 1982; 62: 357–8.

    CAS  Google Scholar 

  29. Olweny CLM, Sikyewunda W, Otim D. Further experience with razoxane in treating Kaposi's sarcoma. Oncology 1980; 37: 174–6.

    PubMed  CAS  Google Scholar 

  30. Kingston RD, Hellmann K. Razoxane for Crohn's colitis and nonspecific proctitis. Br J Clin Pract 1993; 46: 252–5.

    Google Scholar 

  31. Braybrooke JP, O'Byrne KJ, Propper DJ et al. A Phase II Study of Razoxane, an antiangiogenic topoisomerase II inhibitor in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res 2000; 6: 4697–704.

    PubMed  CAS  Google Scholar 

  32. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nature Rev Cancer 2002; 2: 795–803.

    Article  CAS  Google Scholar 

  33. Kingston RD, Fielding JWL, Palmer MK. An evaluation of the effectiveness and safety of razoxane when used as an adjunct to surgery in colorectal cancer. Int J Colorect Dis 1993; 8: 106–10.

    Article  CAS  Google Scholar 

  34. Atherton A. The effect of ICRF 159 on liver metastases from a hamster lymphoma. Eur J Cancer 1975; 11: 383–8.

    PubMed  CAS  Google Scholar 

  35. Peters LJ. A study of the influence of various diagnostic and therapeutic procedures applied to a murine squamous carcinoma on its metastatic behaviour. Br J Cancer 1975; 32: 355–65.

    PubMed  CAS  Google Scholar 

  36. Hellmann K, Hutchinson GE. Unpublished report.

  37. Gilbert JM, Thompson EM, Slavin et al. Inhibition of experimental colorectal cancer by razoxane (ICRF 159). Br J Surg 1984; 71: 600–3.

    PubMed  CAS  Google Scholar 

  38. Baker D, Constable W, Elkon D. The influence of ICRF 159 and levamisole on the incidence of metastases following local irradiation of a solid tumor. Cancer 1981; 48: 2179–83.

    Article  PubMed  CAS  Google Scholar 

  39. Pimm MV, Baldwin RW. Influence of ICRF 159 and Triton WR 1339 on metastases of a rat epithelioma. Br J Cancer 1975; 31: 62–7.

    PubMed  CAS  Google Scholar 

  40. Klenner T, Wingen F, Keppler B et al. Effects on tumour inhibition and survival time of a combination therapy of razoxane (ICRF 159) and two new cytostatica-linked biphosphonates in a transplantable rat osteosarcoma. Clin Exp Metastasis 1988; 6 (Suppl 1): 94.

    Google Scholar 

  41. Hellmann K, Rhomberg W. Radiotherapeutic enhancement by razoxane. Cancer Treat Rev 1991; 18: 225–40.

    Article  PubMed  CAS  Google Scholar 

  42. Herman EH, Mhatre RM, Lee IP et al. Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med 1972; 140: 234–9.

    PubMed  CAS  Google Scholar 

  43. Swain SM, Whaley FS, Gerber MC et al.Delayed administration of Dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin containing therapy. J Clin Oncol 1997; 15: 1333–40.

    PubMed  CAS  Google Scholar 

  44. Bakowski MT. ICRF 159 (±) 1,2-bis(3,5-dioxopiperazine-l-yl) propane, NSC-129, 943; razoxane. Cancer Treat Rev 1976; 3: 95–107.

    PubMed  CAS  Google Scholar 

  45. Hasinoff BB, Hellmann K, Herman EH. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5: 1–28.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Windleshaw House, Withyham, UK

    K. Hellmann

Authors
  1. K. Hellmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hellmann, K. Dynamics of tumour angiogenesis: Effect of razoxane-induced growth rate slowdown. Clin Exp Metastasis 20, 95–102 (2003). https://doi.org/10.1023/A:1022632413888

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022632413888

Search

Navigation